[{"id":"d3399d53-3142-4fb8-8731-3da5f0cf0026","acronym":"TITAN-RCC","url":"https://clinicaltrials.gov/study/NCT02917772","created_at":"2021-08-04T19:53:08.805Z","updated_at":"2025-02-25T14:36:42.250Z","phase":"Phase 2","brief_title":"Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT02917772 - TITAN-RCC","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2022-10-06"}]